X
J&J’s Tremfya gets funding in Germany and UK
https://pharmaphorum.com/news/jjs-tremfya-funding-germany-uk/
psoriasis
FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
AbbVie to file long-acting psoriasis contender
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
Bioelectronic wearable shows promise in psoriasis
Thync’s bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.
J&J’s psoriasis drug faces crowded market after US approval
J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
Novartis’ psoriasis drug gets label boost
New label shows Cosentyx is superior to J&J’s rival in long-term.
Valeant’s Siliq price undercuts rivals to offset black box warning
Siliq will be cheaper than rivals from Novartis and Eli Lilly.
